A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: ER-Positive, HER2-Negative Breast Cancer
Interventions: DRUG: HRS8807|DRUG: HRS8807|DEVICE: HRS8807、SHR6390|DRUG: HRS8807、SHR6390
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.